|Day Low/High||8.18 / 8.25|
|52 Wk Low/High||4.02 / 9.15|
A recent trio of acquisition deals indicates the doldrums in the sector may be over.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Versartis, Adamas and DBV Technologies were among the biotech movers ahead of the market open on Dec. 1.
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
The U.S. Food and Drug Administration has granted orphan drug designation to NewLink's indoximod, a potential treatment for patients with Stage IIb-IV melanoma.
Small biotech stocks have a number of hurdles around FDA approval. Here is how to play that cycle.
Winning FDA approval isn't always a win.
The experiences of three biotechs show how drug approvals don't always translate into stock gains.
Hurricane Harvey was upgraded to a category 2 storm overnight and could be a category 3 before the day is over.
This sector is one of the few areas of the market where you'll find myriad compelling values.